Live news , top stories, corporate news, company news, sector news, economy news, results analysis news, ceo interviews, fund manager interview, advisor interview, market news, bazaar talk, hot stocks news, ipo news, commodities news, mutual fund news, insurance news, news wire
26 October, 2020 18:18 IST
Lupin receives approval for Methylprednisolone tablets USP
Source: IRIS | 25 Feb, 2019, 05.42PM
Rating: NAN / 5 stars.
Comments  |  Post Comment

Pharma major Lupin announced that it has received approval for its Methylprednisolone Tablets USP, 2 mg, 4 mg, 8 mg, 16 mg and 32 mg, from the United States Food and Drug Administration (FDA) to market a generic version of Pharmacia and Upjohn Company‚Äôs Medrol tablets, 2 mg, 4  mg, 8 mg, 16 mg and 32 mg.

Lupin's Methylprednisolone Tablets USP, 2 mg, 4 mg, 8 mg, 16 mg, and 32 mg, is the generic version of Pharmacia and Upjohn Company's Medrol Tablets, 2 mg, 4 mg, 8 mg, 16 mg and 32 mg.

It is indicated to treat Endocrine Disorders, Rheumatic Disorders, Collagen Diseases, Dermatologic Diseases, Allergic States, Ophthalmic Diseases, Respiratory Diseases, Hematologic Disorders, Neoplastic Diseases, Edematous States, Gastrointestinal Diseases, Acute exacerbations of multiple sclerosis, Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate anti-tuberculous chemotherapy, Trichinosis with neurologic or myocardial involvement.

Methylprednisolone Tablets had annual sales of approximately USD 114.3 million in the US (IQVIA MAT December 2018).

Shares of the company declined Rs 0.85, or 0.11%, to settle at Rs 776.00. The total volume of shares traded was 94,041 at the BSE (Monday).

 Post Comment
Name Email
Security Code type    into this box
Related Articles
Home  |   Shares  |   F&O  |   Mutual Funds  |   Loans  |   Insurance  |   News Centre
Wealth Tracker  |   Newsletters  |   Tax Corner  |   NRI Centre  |   Advertise
© All rights reserved. IRIS Business Services Limited
A Disclaimer